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Abstract
Primary response transcription factor, Egr-1, is rapidly activated by a variety of extracellular stimuli. Activation of Egr-1 is shown to
function as a master switch activated by ischemia to trigger expression of pivotal regulators of inflammation, coagulation and vascular
hyperpermeability. Egr-1 is a short-lived protein, but the mechanism that regulates its stability has not yet been clarified. In this study, the
yeast two-hybrid screening revealed that Egr-1 interacts significantly with PRC8 (proteasome component C8) and the specific interaction was
confirmed by GST pull-down assay and coimmunoprecipitation. Interestingly, we found that the PRC8-mediated regulation of Egr-1 activity
is associated with the proteasome pathway and PRC8 inhibits the transcriptional activity of Egr-1. In addition, Egr-1 protein was specifically
multiubiquitinated by ubiquitin. These data strongly imply that Egr-1 protein is targeted for proteolysis by the ubiquitin-dependent
proteasome pathway.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Egr-1 is a zinc finger transcription factor and one of im-
mediate early response genes in a multigene family that in-
cludes Egr-2, Egr-3, Egr-4 and WT1 [1,2]. Egr-1 is an 80–
82 kDa protein consisting of 533 amino acids, discovered
independently by a number of laboratories searching for fac-
tors regulating cell growth and proliferation [1,3]. In addi-
tion, Egr-1 is upregulated in response to a wide variety of mi-
togenic and nonmitogenic stimuli, including peptide growth
factors, shear stress, urea, hypotonicity and hypoxia [4–9]. It
is thus likely that Egr-1 protein levels are critically regula-
ted during development, differentiation and tumorigenesis.
Once activated, Egr-1 binds to 5V-GCG(G/T)GGGCG-3V
consensus sequences within the promoter region of target
genes, resulting in transcriptional activation or repression.
Egr-1 bound to DNA alters gene transcription through
mechanisms dependent on both coactivators and corepres-
sors. Transcriptional coactivators, such as CBP and p300,
can interact with the activation region of Egr-1 and increase
the transcriptional activity of Egr-1 [10]. Corepressors such
as NAB1 and NAB2 also interact with Egr-1 and negatively
regulate Egr-1 activity [11,12].
In view of protein stability, Egr-1 is a short-lived protein
with a half-life of less than 2 h [2]. However, the mechanism
underlying the regulation of the stability of the Egr-1 protein
has not yet been elucidated. Recently, it has been shown that
the degradation of various transcription factors, such as c-
Jun [13], c-Fos [14], STAT1 [15], p53 [16] and c-Myc [17],
is mediated by the ubiquitin–proteasome pathway, which is
a major route of intracellular degradation of short-lived
regulatory proteins [18].
In this paper, we demonstrate that PRC8, a-type subunit
of 20S proteasome core complex, interacts with Egr-1,
leading to the ubiquitin-dependent proteasome degradation
of Egr-1.
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2. Materials and methods
2.1. Materials
E64 and ALLM were purchased from Sigma. ALLnL,
MG132 and lactacystin, were purchased from Calbiochem.
Egr-1, a-tubulin and FLAG antibodies were purchased from
Santa Cruz Biotechnology, InnoGenex and Sigma, respec-
tively.
2.2. Plasmids
For the yeast two-hybrid screening, we amplified the C-
terminal region of Egr-1 spanning amino acids 420–543
by PCR and subcloned into the pBHA. To construct PRC8
expression vector, PRC8 cDNA was inserted into the
pCMV-Tag2 (Stratagene). Egr-1 expression vector was
also constructed by PCR and subcloned into the pCMV-
Tag2 (Stratagene). FLAG-Ub vector was kindly provided
from Dr. H. Yokosawa (Hokkaido University, Sapporo,
Japan).
2.3. Two-hybrid library screening and evaluation of
protein–protein interactions
Yeast strains SFY526 and L40 obtained from CLON-
TECH were used to assay protein–protein interactions and
for library screening, respectively. Two-hybrid assays using
the LexA system were performed according to the instruc-
tions of the manufacturer (CLONTECH).
2.4. GST pull-down assays
[35S]Methioine-labeled in vitro translated Egr-1 was
prepared by using the TNT system (Promega). GST fusion
proteins were purified as described previously [19]. Equal
amounts (f 1 Ag) of GST or GST-PRC8 immobilized on
glutathione sepharose beads was incubated with [35S]Egr-1
in reaction buffer (10 mM Tris, pH 8.0, 150 mM NaCl, 1
mM EDTA, 0.1% NP-40) at 4 jC. After washing, the
bound proteins were eluted with the sample buffer and
were separated by SDS-PAGE, followed by autoradiogra-
phy.
2.5. Coimmunoprecipitation
After 24 h of transfection into HEK 293 cells, the cells
were washed with PBS. The preparation of protein extracts,
immunoprecipitation and Western blot were performed as
described previously [20].
2.6. Luciferase assay
The human IGF-II P3 construct, Hup3 [21], was used as
luciferase reporter plasmid. The 0.4 Ag each of Hup3 and
pCMV/h-gal with or without 1 Ag of Egr-1/PRC8 were
transfected to HEK 293 cells. Luciferase assay was per-
formed as described previously [22].
2.7. Ubiquitination assay
After transfection of pCMV-Egr-1 and FLAG-Ub to HEK
293 cells, 24 h later, the cells were treated with 5 AM of
MG132 for 12 h. Cell lysates were immunoprecipitated with
Egr-1 antibody. Precipitated proteins were separated by
SDS-PAGE and immunoblotted with FLAG antibody.
3. Results
3.1. Egr-1 interacts with the PRC8 through the C-terminal
region
The yeast two-hybrid system was used to identify can-
didate proteins that interact with Egr-1. As shown in Fig.
1A, mouse embryonic 17-day cDNA library was screened
with the C-terminal region of Egr-1 as a bait. From 6 106
transformants, 92 His + /Lac + double-positive clones were
isolated. The 16 clones were further selected by h-galacto-
sidase assays in another strain, SFY526. DNA sequence and
Fig. 1. Association of Egr-1 with PRC8. (A) Structures of Egr-1 proteins
tested in yeast two-hybrid screening are shown. TAD, transactivation
domain; DBD, DNA binding domain; R1, repression domain. (B) In vitro
translated Egr-1 was incubated with GST-PRC8, washed, and separated by
SDS-PAGE. (C) pCMV-Egr-1 was transfected into HEK293 cells together
with pCMV-PRC8. Cells were lysed and immunoprecipitated with Egr-1
antibody. Immunopurified proteins were analyzed by Western blot with
FLAG antibody. W, Western blot.
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database searches revealed that the nucleotide sequence of
12 clones encoded mouse PRC8.
3.2. Egr-1 interacts with PRC8
To confirm that PRC8 interacts with Egr-1, we performed
GST pull-down assays. As expected, Egr-1 was pulled
down with GST-PRC8 but not with GST alone (Fig. 1B),
confirming that the interaction between PRC8 and Egr-1 is
specific in vitro. To further verify this interaction, we
performed coimmunoprecipitation assay. As shown in Fig.
1C, Egr-1 strongly interacts with PRC8.
3.3. Association of Egr-1 with PRC8 causes its degradation
through the proteasome pathway
Association of Egr-1 with PRC8 raised the possibility
that Egr-1 could be degraded through a PRC8-dependent
proteasome degradation pathway. To investigate whether
this pathway plays an important role in the degradation of
Egr-1, we first examined the effects of proteasome and
protease inhibitors on the steady-state level of Egr-1 protein
(Fig. 2A). Treatment with the proteasome-specific inhibi-
tors, ALLnL, MG132 and lactacystin on HepG2 cells,
resulted in elevation of Egr-1 protein levels remarkably,
but not with nonproteasome inhibitors such as E64 and
ALLM. To study whether the above effects are specific at
the protein level, we also examined the effects of the
proteasome inhibitors on the level of Egr-1 mRNA, and
found that any of the inhibitors did not change the expres-
sion of Egr-1 mRNA (Fig. 2B). Next, to determine whether
Fig. 2. Effects of proteosome-specific inhibitors on the levels of Egr-1
protein and mRNA. (A) HepG2 cells were treated with proteosome and
protease inhibitors for 4 h. The total proteins were analyzed by Western
blotting with Egr-1 and a-tubulin antibodies, respectively. (B) Total RNA
was extracted and the levels of Egr-1 and h-actin mRNAwere analyzed by
RT-PCR. (C) Effect of proteasome-specific inhibitor on the stability of Egr-
1 protein. HepG2 cells were treated with 50 AM MG132 or 0.25% DMSO
for 1 h followed by incubation with cycloheximide (CHX) at a
concentration of 25 Ag/ml for the indicated periods. The cell lysates were
prepared and the protein levels of Egr-1 were analyzed by Western blotting
with Egr-1 antibody.
Fig. 3. Destabilization of Egr-1 by PRC8. pCMV-Egr-1 was cotransfected
with or without pCMV-PRC8, as indicated. Total cell lysates were subjected
to Western blotting. Egr-1 and PRC8 were detected with FLAG antibody.
Fig. 4. PRC8 inhibits the transcriptional activity of Egr-1. HEK293 cells
were transfected with 0.4 Ag each of the reporter plasmid Hup3 and 1 Ag of
pCMV-Egr-1, and 0.5 Ag of pCMV/h-gal together with 1 Ag of pCMV-
PRC8. Luciferase activities were normalized to h-galactosidase activities.
This is a representative of three independent experiments that were done in
duplicate.
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the proteasome inhibitor directly affects degradation of Egr-
1 protein, we measured its effects on the stability of Egr-1
protein under conditions in which protein synthesis had
been blocked by cycloheximide. As shown in Fig. 2C, Egr-1
protein was stabilized in the presence of MG132, indicating
that the proteasome inhibitor directly inhibited degradation
of the Egr-1 protein. These results demonstrate that Egr-1
protein is degraded by the 26S proteasome.
3.4. PRC8 destabilizes Egr-1
PRC8 is a subunit of the 26S proteasome complex that
degrades poly-ubiquitinated proteins. Since our results pro-
vided evidence that PRC8 interacts with Egr-1 and the
proteasome-specific inhibitors increased the stability of
Egr-1 protein, we examined whether PRC8 affect the
stability of Egr-1 protein through the proteasome-dependent
pathway. Interestingly, coexpression of PRC8 decreased the
Egr-1 protein level (Fig. 3), suggesting that PRC8 destabil-
izes Egr-1.
3.5. Effects of PRC8 on the transcriptional activity of Egr-1
We then performed luciferase reporter assays to test
whether PRC8 regulates the transactivation activity of
Egr-1 through the regulation of the stability of Egr-1. As
shown in Fig. 4, transfection of pCMV-Egr-1 with the
reporter plasmid resulted in an increase of the luciferase
activity. In contrast, cotransfection of pCMV-PRC8
decreased the transactivation activity of Egr-1, indicating
that PRC8 inhibits the transcriptional activity of Egr-1.
3.6. Egr-1 is multiubiquitinated
We next investigated whether Egr-1 could be ubiquiti-
nated or not. Transiently expressed Egr-1 protein produced
high molecular mass bands even under SDS-PAGE and the
presence of these bands suggested the ability of Egr-1 to
produce a variety of stable protein complexes including
Ub–Egr-1 complexes that was dependent on MG132 con-
centration (data not shown). To confirm whether Egr-1
protein is multiubiquitinated before degradation by 26S
proteasome, we transiently overexpressed both FLAG-Ub
and Egr-1 in HEK293 cells simultaneously. High molecular
mass materials, detected by FLAG antibody, accumulated
extremely in the case of cotransfection with Ub and Egr-1
expression plasmids (Fig. 5). Altogether, these results
strongly suggest that Egr-1 protein is multiubiquitinated
before its degradation by the 26S proteasome.
4. Discussion
Expression of Egr-1 is probably closely regulated under
normal conditions. Overexpression of Egr-1 has been shown
in Burkitt lymphoma [23]. In contrast, loss of Egr-1 expres-
sion has been shown to confer an immortalized phenotype
in several murine and human cell lines [23]. Moreover, low
expression of Egr-1 has been demonstrated in human lung
cancer compared with normal lung tissue [24]. However,
our previous results indicated that Egr-1 is directly involved
in the expression of IGF-II [8], which is expressed in most
of the cirrhotic and human hepatocellular carcinoma tissues
[25,26] and has an angiogenic activity [27,28]. Thus, altered
gene expression of Egr-1 may be an important step in the
progression of cells from normal to the malignant pheno-
type. However, posttranslational regulation mechanism of
Egr-1 protein is not clear.
The selective degradation of many short-lived proteins in
eukaryotic cells is carried out by the ubiquitin-dependent
26S proteasome [29]. The 26S proteasome is a 2.5-MDa
molecular machine built from f 31 different subunits,
which catalyzes protein degradation [29]. The 26S protea-
some complex is a ubiquitous multicatalytic protease com-
plex composed of two large complexes: the 20S catalytic
core complex and the 19S regulatory complex [30]. The 19S
complex is required for the recognition of poly-ubiquiti-
nated protein substrates that are degraded inside of the 20S
core complex. The barrel-shaped 20S particle is made up of
four rings, each of which contains seven different subunits.
The two inner rings contain h-type subunits and the outer
rings comprise a-type subunits. The proteasome is involved
in many different cellular processes, ranging from the cell
cycle process to antigen processing [29]. Recently, there
have been several reports about cellular regulatory proteins
and viral proteins that interact with subunits of the protea-
some complex and participate in the proteasome-dependent
regulation [31–33].
In our work, the specificity of PRC8 interaction with
Egr-1 was markedly demonstrated in a yeast two-hybrid
assay and was further confirmed in vitro (Fig. 1). These
results indicated that PRC8 is involved in the regulation of
Egr-1. Significantly, PRC8-mediated regulation of Egr-1
activity is associated with the proteasome pathway (Figs.
2 and 3) and we showed that PRC8 decreased the transcrip-
Fig. 5. Ubiquitination of Egr-1. HEK293 cells were transiently transfected
with the indicated combinations of FLAG-Ub and pCMV-Egr-1, and 24 h
after transfection, the cells were treated with 5 AM MG132 for 12 h. The
bracket indicates multiubiquitinated Egr-1. Cell lysates were directly
subjected to Western blotting with FLAG antibody to check the expression
level of FLAG-Ub. H, IgG heavy chain.
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tional activity of Egr-1 (Fig. 4). These negative regulation of
Egr-1 by PRC8 may be due to the PRC8-mediated recruit-
ment of Egr-1 to the proteasome complex. We further
demonstrated that Egr-1 is multiubiquitinated (Fig. 5).
Thereby, PRC8 might be required for rapid degradation of
the Egr-1 protein through the ubiquitin–proteasome system.
Our finding is consistent with previous reports that
various short-lived transcription factors are degraded by
ubiquitin–proteasome pathway [13–17]. Especially, this is
the first report of Egr-1 protein degradation mechanism
through the ubiquitin–proteasome pathway. Taken together,
these results strongly imply that Egr-1 protein is targeted for
proteolysis by the ubiquitin-dependent proteasome pathway
through association with PRC8. In addition, it can be
suggested that the action of Egr-1 on cell cycle progression,
development and tumorigenesis is controlled through deg-
radation by the ubiquitin–proteasome pathway.
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